RNL Bio files IND with Korean FDA to transplant adult stem cells to treat cerebral palsy: what’s the scoop?

The Korean-based stem cell biotech, RNL Bio, which also does business in the U.S. as RNL Bio and Human Biostar Inc, reportedly (seems to be a press release, PR) has filed an investigational new drug (IND) application with the Korean FDA (KFDA). The purpose of the application is to test the efficacy of autologous adult stem cells …

RNL Bio files IND with Korean FDA to transplant adult stem cells to treat cerebral palsy: what’s the scoop? Read More »